Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Senior Vice President | April 21, 2020 | April 24, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date April 21, 2020 · Filed April 24, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 62,205 |
Ending reported balance
After 2020-04-21 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2020-04-21 · Exercise / conversion · Acquired 46,016 · Balance 83,035 Row 2 · 2020-04-21 · Exercise / conversion · Acquired 36,715 · Balance 119,750 Row 3 · 2020-04-21 · Exercise / conversion · Acquired 25,681 · Balance 145,431 Row 4 · 2020-04-21 · Tax withholding · Disposed 83,226 · Balance 62,205 |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.40 · Expires 2027-02-16 | Direct | 0 |
Reported balance
After 2020-04-21 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-04-21 · Exercise / conversion · Disposed 46,016 · Balance 0 F5: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.94 · Expires 2028-02-15 | Direct | 36,715 |
Reported balance
After 2020-04-21 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-04-21 · Exercise / conversion · Disposed 36,715 · Balance 36,715 F6: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $75.90 · Expires 2029-02-21 | Direct | 51,364 |
Reported balance
After 2020-04-21 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2020-04-21 · Exercise / conversion · Disposed 25,681 · Balance 51,364 F6: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 22 |
Reported balance
Holding disclosure · report date 2020-04-21 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 22 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of April 21, 2020. |
| Common shares without par valueSEC Table I · non-derivative | IndirectJaime Contreras Marvan 2006 Living Trust | 176,217 |
Reported balance
Holding disclosure · report date 2020-04-21 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 176,217 F2: Held in the Jaime Contreras Marvan 2006 Living Trust. The reporting person is sole trustee of the trust. The trust is revocable. |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy Spouse | 2,624 |
Reported balance
Holding disclosure · report date 2020-04-21 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 2,624 F3: The reporting person disclaims beneficial ownership of all securities held by his spouse. |
| Common shares without par valueSEC Table I · non-derivative | IndirectLiving Trust (by spouse) | 12,081 |
Reported balance
Holding disclosure · report date 2020-04-21 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 12,081 F4: Held in spouse's living trust. The reporting person's spouse is sole trustee of the trust. The trust is revocable. The reporting person disclaims beneficial ownership of these securities. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of April 21, 2020.
F2: Held in the Jaime Contreras Marvan 2006 Living Trust. The reporting person is sole trustee of the trust. The trust is revocable.
F3: The reporting person disclaims beneficial ownership of all securities held by his spouse.
F4: Held in spouse's living trust. The reporting person's spouse is sole trustee of the trust. The trust is revocable. The reporting person disclaims beneficial ownership of these securities.
F5: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
F6: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2018 Filed Apr 3, 2018 22:07 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,376 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-005308 · edgar.xml · nonDerivative · entry 4 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 3,786 F3 · shares: This grant represents a restricted stock unit award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting on each anniversary of the grant date. The award includes the right to have stock withheld for tax purposes. F4 · balance_after: The reporting person disclaims beneficial ownership of all securities held by his spouse. Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 22:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,900 | $60.00 | $294,000.00 |
DisclosureSEC source: 0001179110-18-003309 · edgar.xml · nonDerivative · entry 3 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,436 Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 22:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,384 | $58.80 | $81,380.58 |
DisclosureSEC source: 0001179110-18-003309 · edgar.xml · nonDerivative · entry 2 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,336 Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 8,649 | $60.55 | $523,696.95 |
DisclosureSEC source: 0001179110-18-003309 · edgar.xml · nonDerivative · entry 1 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,720 Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:37 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 110,146 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001179110-18-002533 · edgar.xml · derivative · entry 6 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,146 Underlying: Common shares · 110,146 shares Expires 2028-02-15 F6 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 36,716 on 02/16/2019, 36,715 on 02/16/2020, and 36,715 on 02/16/2021. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:37 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 20,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002533 · edgar.xml · nonDerivative · entry 1 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,369 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 21:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 22,000 | $0.00 Strike: $27.03 | $0.00 |
DisclosureSEC source: 0001179110-17-012721 · edgar.xml · derivative · entry 22 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 22,000 shares Expires 2022-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 21:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 17,300 | $0.00 Strike: $22.39 | $0.00 |
DisclosureSEC source: 0001179110-17-012721 · edgar.xml · derivative · entry 21 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 17,300 shares Expires 2021-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 21:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 13,400 | $0.00 Strike: $26.19 | $0.00 |
DisclosureSEC source: 0001179110-17-012721 · edgar.xml · derivative · entry 20 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 13,400 shares Expires 2020-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 21:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,200 | $52.04 | $62,449.20 |
DisclosureSEC source: 0001179110-17-012721 · edgar.xml · nonDerivative · entry 15 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,339 Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 21:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,200 | $52.04 | $62,448.00 |
DisclosureSEC source: 0001179110-17-012721 · edgar.xml · nonDerivative · entry 14 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,539 Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 21:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 500 | $52.03 | $26,015.00 |
DisclosureSEC source: 0001179110-17-012721 · edgar.xml · nonDerivative · entry 13 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,739 Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 21:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $52.03 | $10,405.00 |
DisclosureSEC source: 0001179110-17-012721 · edgar.xml · nonDerivative · entry 12 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,239 Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 21:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,600 | $52.02 | $83,232.00 |
DisclosureSEC source: 0001179110-17-012721 · edgar.xml · nonDerivative · entry 11 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,439 Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 21:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,816 | $52.01 | $198,470.16 |
DisclosureSEC source: 0001179110-17-012721 · edgar.xml · nonDerivative · entry 10 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,039 Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 21:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,109 | $52.00 | $57,668.00 |
DisclosureSEC source: 0001179110-17-012721 · edgar.xml · nonDerivative · entry 9 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,855 Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 21:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 909 | $51.99 | $47,258.91 |
DisclosureSEC source: 0001179110-17-012721 · edgar.xml · nonDerivative · entry 8 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,964 Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 21:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,913 | $51.98 | $99,437.74 |
DisclosureSEC source: 0001179110-17-012721 · edgar.xml · nonDerivative · entry 7 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,873 Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 21:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,701 | $51.97 | $88,400.97 |
DisclosureSEC source: 0001179110-17-012721 · edgar.xml · nonDerivative · entry 6 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,786 Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 21:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,152 | $51.96 | $215,737.92 |
DisclosureSEC source: 0001179110-17-012721 · edgar.xml · nonDerivative · entry 5 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,487 Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 21:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 34,400 | $51.95 | $1,787,080.00 |
DisclosureSEC source: 0001179110-17-012721 · edgar.xml · nonDerivative · entry 4 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,639 Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 21:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 22,000 | $27.03 | $594,739.20 |
DisclosureSEC source: 0001179110-17-012721 · edgar.xml · nonDerivative · entry 3 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,039 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 21:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 17,300 | $22.39 | $387,379.87 |
DisclosureSEC source: 0001179110-17-012721 · edgar.xml · nonDerivative · entry 2 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,039 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 21:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 13,400 | $26.19 | $350,917.86 |
DisclosureSEC source: 0001179110-17-012721 · edgar.xml · nonDerivative · entry 1 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,739 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 767 | $44.64 | $34,239.65 |
DisclosureSEC source: 0001179110-17-005577 · edgar.xml · nonDerivative · entry 6 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 2,410 F4 · balance_after: The reporting person disclaims beneficial ownership of all securities held by his spouse. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 375 | $44.55 | $16,706.25 |
DisclosureSEC source: 0001179110-17-005577 · edgar.xml · nonDerivative · entry 5 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 3,177 F4 · balance_after: The reporting person disclaims beneficial ownership of all securities held by his spouse. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,126 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-005577 · edgar.xml · nonDerivative · entry 4 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 3,552 F3 · shares: This grant represents a restricted stock unit award under the Abbott Laboratories 2009 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting on each anniversary of the grant date. The award includes the right to have stock withheld for tax purposes. F4 · balance_after: The reporting person disclaims beneficial ownership of all securities held by his spouse. Read SEC document |
| March 21, 2017 Filed Mar 24, 2017 21:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 394 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-005133 · edgar.xml · nonDerivative · entry 2 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · Jaime Contreras Marvan 2006 Living Trust Disclosed balance after: 64,297 F1 · balance_after: Held in the Jaime Contreras Marvan 2006 Living Trust. The reporting person is sole trustee of the trust. The trust is revocable. Read SEC document |
| March 21, 2017 Filed Mar 24, 2017 21:06 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 394 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-005133 · edgar.xml · nonDerivative · entry 1 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,339 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,055 | $45.01 | $137,505.55 |
DisclosureSEC source: 0001179110-17-003664 · edgar.xml · nonDerivative · entry 3 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,733 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 10,100 | $45.02 | $454,651.50 |
DisclosureSEC source: 0001179110-17-003664 · edgar.xml · nonDerivative · entry 2 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,788 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 8,740 | $45.46 | $397,320.40 |
DisclosureSEC source: 0001179110-17-003664 · edgar.xml · nonDerivative · entry 1 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,888 Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 22:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 138,049 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001179110-17-002921 · edgar.xml · derivative · entry 6 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,049 Underlying: Common shares · 138,049 shares Expires 2027-02-16 F6 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 46,017 on 02/17/2018, 46,016 on 02/17/2019, and 46,016 on 02/17/2020. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 22:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 19,961 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002921 · edgar.xml · nonDerivative · entry 1 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,628 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| March 31, 2016 Filed Apr 1, 2016 21:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 138 | $41.78 | $5,766.22 |
DisclosureSEC source: 0001179110-16-022538 · edgar.xml · nonDerivative · entry 8 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 2,426 Read SEC document |
| March 31, 2016 Filed Apr 1, 2016 21:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 162 | $41.79 | $6,769.17 |
DisclosureSEC source: 0001179110-16-022538 · edgar.xml · nonDerivative · entry 7 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 2,564 Read SEC document |
| March 31, 2016 Filed Apr 1, 2016 21:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 162 | $41.78 | $6,769.04 |
DisclosureSEC source: 0001179110-16-022538 · edgar.xml · nonDerivative · entry 6 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 2,726 Read SEC document |
| March 31, 2016 Filed Apr 1, 2016 21:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 212 | $41.65 | $8,829.80 |
DisclosureSEC source: 0001179110-16-022538 · edgar.xml · nonDerivative · entry 5 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 2,888 Read SEC document |
| March 31, 2016 Filed Apr 1, 2016 21:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,406 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-022538 · edgar.xml · nonDerivative · entry 4 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 3,100 F3 · shares: This grant represents a restricted stock unit award under the Abbott Laboratories 2009 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting on each anniversary of the grant date. The award includes the right to have shares withheld for tax purposes. F4 · balance_after: The reporting person disclaims beneficial ownership of all securities held by his spouse. Read SEC document |
| February 29, 2016 Filed Mar 3, 2016 00:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,500 | $38.95 | $58,420.50 |
DisclosureSEC source: 0001179110-16-020737 · edgar.xml · nonDerivative · entry 4 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,667 Read SEC document |
| February 29, 2016 Filed Mar 3, 2016 00:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 9,017 | $38.94 | $351,094.93 |
DisclosureSEC source: 0001179110-16-020737 · edgar.xml · nonDerivative · entry 3 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,167 Read SEC document |
| February 29, 2016 Filed Mar 3, 2016 00:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $38.94 | $3,893.50 |
DisclosureSEC source: 0001179110-16-020737 · edgar.xml · nonDerivative · entry 2 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,184 Read SEC document |
| February 29, 2016 Filed Mar 3, 2016 00:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 6,283 | $39.52 | $248,304.16 |
DisclosureSEC source: 0001179110-16-020737 · edgar.xml · nonDerivative · entry 1 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,284 Read SEC document |
| February 19, 2016 Filed Feb 23, 2016 23:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 242,579 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-16-019915 · edgar.xml · derivative · entry 6 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,579 Underlying: Common shares · 242,579 shares Expires 2026-02-18 F6 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 80,860 on 02/19/2017, 80,859 on 02/19/2018, and 80,860 on 02/19/2019. Read SEC document |
| February 19, 2016 Filed Feb 23, 2016 23:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 27,669 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-019915 · edgar.xml · nonDerivative · entry 1 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,567 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 16, 2016 Filed Feb 17, 2016 22:56 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 254 | $37.87 | $9,617.71 |
DisclosureSEC source: 0001179110-16-019501 · edgar.xml · nonDerivative · entry 5 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,694 Read SEC document |
| February 15, 2016 Filed Feb 17, 2016 22:56 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 146 | $37.13 | $5,420.98 |
DisclosureSEC source: 0001179110-16-019501 · edgar.xml · nonDerivative · entry 4 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,948 Read SEC document |
| March 31, 2015 Filed Apr 2, 2015 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 228 | $46.43 | $10,586.27 |
DisclosureSEC source: 0001179110-15-005829 · edgar.xml · nonDerivative · entry 6 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 2,094 Read SEC document |
| March 31, 2015 Filed Apr 2, 2015 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 99 | $47.08 | $4,660.92 |
DisclosureSEC source: 0001179110-15-005829 · edgar.xml · nonDerivative · entry 5 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 2,322 Read SEC document |
| March 31, 2015 Filed Apr 2, 2015 21:03 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-005829 · edgar.xml · nonDerivative · entry 4 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 2,421 F3 · shares: This grant represents a restricted stock unit award under the Abbott Laboratories 2009 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting on each anniversary of the grant date. The award includes the right to have stock withheld for tax purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.